We believe that Phytomedicine will effectively treat previously unmet medical needs and improve the lives of patients, impacting public health across the world.

MGC embraces this by creating Phytocannabinoid-based medicine products and providing them in targeted markets. These products are registered for sale and leverage the Company’s own proprietary medical cannabis formula through clinical trials in Europe, Israel and Australia. In addition, tertiary and supplementary revenue streams solidify our presence in the market.

This enables future medical product sales across the European Union, Australia, and other geographies, following the requisite legal and regulatory approvals.